Astellas Pharma Global Development, Inc. $4503.T
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS22
PHASE 3 / 2-310
RECRUITING11
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO62%
Delay Index: of 13 active trials registered more than a year ago, 8 have moved their primary completion (readout) date by more than 6 months since first registration (median +18.0 months). See all sponsors →
Open Astellas Pharma Global Development, Inc. on the live radar map → 📅 $4503.T readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Spotlight NCT03504397 |
P3 | Active, not recruiting | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | 565 | 2022-09-09 (+19 mo) |
| GLOW NCT03653507 |
P3 | Active, not recruiting | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | 507 | 2022-10-25 (+15 mo) |
| EV-302 NCT04223856 |
P3 | Active, not recruiting | Urothelial Cancer | 886 | 2023-08-08 (-3 mo) |
| enfortumab vedotin NCT04225117 |
P2 | Active, not recruiting | Locally Advanced or Metastatic Malignant Solid Tumors | 329 | 2025-02-25 (+23 mo) |
| Fezolinetant NCT06440967 |
P3 | Active, not recruiting | Hot Flashes | 982 | 2026-06-25 (-4 mo) |
| zolbetuximab NCT03816163 |
P2 | Active, not recruiting | Pancreatic Cancer; Metastatic Pancreatic Cancer | 393 | 2026-10-31 (+57 mo) |
| XNW27011 NCT06792435 |
P1/2 | Active, not recruiting | Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC) | 240 | 2026-12-30 (+18 mo) |
| ILUSTRO NCT03505320 |
P2 | Active, not recruiting | Pharmacokinetics of Zolbetuximab; Gastric Cancer | 143 | 2027-06-30 (+87 mo) |
| Roxadustat NCT05970172 |
P3 | Active, not recruiting | Chronic Kidney Disease; Renal Anemia | 98 | 2027-10-30 (+23 mo) |
| Enfortumab Vedotin NCT07475806 |
P2 | Recruiting | Muscle-invasive Bladder Cancer | 240 | 2027-11-30 |
| Gilteritinib NCT05520567 |
P1/2 | Active, not recruiting | Acute Myeloid Leukemia (AML); FLT3-mutated Acute Myeloid Leukemia | 70 | 2028-07-31 (+5 mo) |
| LUCERNA NCT06901531 |
P3 | Recruiting | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | 500 | 2028-09-30 (-15 mo) |
| ASP2998 NCT07287995 |
P1/2 | Recruiting | Locally Advanced or Metastatic Malignant Solid Tumors | 428 | 2029-06-30 |
| enzalutamide NCT02960022 |
P2 | Active, not recruiting | Prostate Cancer | 900 | 2029-07-31 (+98 mo) |
| ASP546C NCT07488676 |
P1/2 | Recruiting | Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma; Pancreatic Adenocarcinoma | 150 | 2029-07-31 |
| Setidegrasib NCT07409272 |
P3 | Recruiting | Pancreatic Cancer; Metastatic Pancreatic Cancer | 614 | 2029-08-31 |
| ASP388B NCT07730021 |
P1/2 | Recruiting | Locally Advanced or Metastatic Solid Tumors | 392 | 2030-02-28 |
| Enfortumab vedotin NCT07566156 |
P3 | Recruiting | Urothelial Cancer; Urinary Bladder Neoplasms | 390 | 2030-03-31 |
| Setidegrasib NCT07566052 |
P3 | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 356 | 2030-06-30 |
| ASP2767 NCT07770685 |
P1/2 | Recruiting | Glaucoma | 156 | 2030-07-31 |
| ASP2138 NCT07673887 |
P3 | Recruiting | Gastric Adenocarcinoma; Gastroesophageal Junction (GEJ) Adenocarcinoma | 570 | 2031-02-28 |
| ASP5541 NCT07005154 |
P2 | Recruiting | Prostate Cancer; Metastatic Castration-Resistant Prostate Cancer | 218 | 2032-05-31 |